Brand name for RAD001( Everolimus) marketed by NOVARTIS. AFINITOR is a once-daily oral inhibitor of mTOR ( Mammalian Target of Rapamycin) for patients with advanced renal cell carcinoma (RCC;  Renal Cancer) whose disease has progressed on or after treatment with  Sorafenib or  Sunitinib therapy targeting  Vascular Endothelial Growth Factor (VEGF).